BlossomHill Therapeutics, Inc. (NASDAQ:BLSM) Given Consensus Rating of “Moderate Buy” by Brokerages

BlossomHill Therapeutics, Inc. (NASDAQ:BLSM) has been given an average rating of “Moderate Buy” by the six ratings firms that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $32.20.

Several equities research analysts have issued reports on the stock. Wall Street Zen upgraded shares of BlossomHill Therapeutics to a “hold” rating in a research note on Saturday, August 15th. Zacks Research upgraded BlossomHill Therapeutics to a “hold” rating in a report on Wednesday, September 2nd. HC Wainwright started coverage on BlossomHill Therapeutics in a research report on Tuesday, September 1st. They issued a “buy” rating and a $35.00 target price on the stock. Leerink Partners initiated coverage on BlossomHill Therapeutics in a report on Tuesday, September 1st. They set an “outperform” rating and a $36.00 target price on the stock. Finally, Guggenheim assumed coverage on BlossomHill Therapeutics in a research report on Tuesday, September 1st. They set a “buy” rating and a $30.00 price target for the company.

BlossomHill Therapeutics Price Performance

NASDAQ BLSM opened at $22.01 on Tuesday. BlossomHill Therapeutics has a 12-month low of $15.25 and a 12-month high of $22.16.

Insider Buying and Selling

In other news, General Counsel Vincent Liptak bought 2,200 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The stock was acquired at an average cost of $16.00 per share, with a total value of $35,200.00. Following the completion of the purchase, the general counsel owned 111,412 shares of the company’s stock, valued at $1,782,592. This represents a 2.01% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director John P. Schmid bought 6,000 shares of the stock in a transaction that occurred on Monday, August 10th. The shares were purchased at an average price of $16.00 per share, for a total transaction of $96,000.00. Following the completion of the acquisition, the director owned 6,000 shares of the company’s stock, valued at $96,000. The trade was a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired a total of 1,573,900 shares of company stock worth $25,181,900 in the last quarter.

BlossomHill Therapeutics Company Profile

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company’s lead clinical programs include BH-30643. BlossomHill Therapeutics Inc is headquartered in San Diego, California.